Physician profile
Kurt A Duncan
NPI 1851540736
$9,074.50
in general payments reported to CMS, 2019-2025
33 companies · $3,987 in 2025
The $3,987 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $794 · 2021: $894 · 2022: $1,914 · 2023: $495 · 2024: $802 · 2025: $3,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,690 · Food and Beverage: $2,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,689.71 |
| Food and Beverage | $2,593.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,384.73 | 2020-2025 | General - Vascular Access, Avvigo Guidance System, Opticross 35 |
| Medtronic, INC. | $824.31 | 2022-2023 | Hawkone, Spiderfx |
| Abiomed | $756.70 | 2020-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $495.38 | 2019-2025 | Lifevest |
| Philips North America LLC | $448.04 | 2020-2024 | (7881) US Und |
| Novartis Pharmaceuticals Corporation | $300.69 | 2019-2025 | |
| Inari Medical, INC. | $289.61 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $267.61 | 2020-2025 | Camzyos, Eliquis |
| Pfizer INC. | $147.05 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $126.40 | 2021-2022 | |
| Cook Medical LLC | $105.18 | 2020-2025 | Zilver Ptx |
| Kestra Medical Technology Services, INC. | $95.31 | 2025 | Assure Wcd |
| Amarin Pharma, INC. | $80.41 | 2019-2021 | |
| Abbott Laboratories | $79.12 | 2019-2020 | |
| Terumo Medical Corporation | $71.19 | 2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.75 | 2019-2024 | Jardiance |
| Amgen INC. | $66.37 | 2019-2025 | Repatha |
| Biosense Webster, INC. | $65.75 | 2022-2023 | Soundstar, Carto 3 |
| Angiodynamics, INC. | $56.25 | 2021-2023 | Auryon Laser System 100-120 Vac |
| Bard Peripheral Vascular, INC. | $54.81 | 2023 | Venovo |
| Astrazeneca Pharmaceuticals LP | $49.30 | 2021 | |
| Edwards Lifesciences Corporation | $47.62 | 2025 | |
| Merck Sharp & Dohme LLC | $28.82 | 2023 | Verquvo |
| Impulse Dynamics (USA) INC. | $24.55 | 2023 | Optimizer |
| Cvrx, INC. | $21.73 | 2023 | Barostim Neo System |
| Itamar Medical INC | $20.58 | 2024 | Watchpatone |
| Bayer Healthcare Pharmaceuticals INC. | $17.79 | 2021 | |
| Cardiva Medical, INC. | $16.98 | 2021 | |
| Novo Nordisk INC | $16.57 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $14.59 | 2025 | Nexletol |
| Medela LLC | $11.99 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.72 | 2019 | |
| Kerecis Limited | $9.60 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.